Arrowhead Depreciation And Amortization vs Selling General Administrative Analysis

0HI3 Stock

26.30 4.45 20.37%

Arrowhead Pharmaceuticals financial indicator trend analysis is way more than just evaluating Arrowhead Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arrowhead Pharmaceuticals is a good investment. Please check the relationship between Arrowhead Pharmaceuticals Depreciation And Amortization and its Selling General Administrative accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.

Depreciation And Amortization vs Selling General Administrative

Depreciation And Amortization vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arrowhead Pharmaceuticals Depreciation And Amortization account and Selling General Administrative. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Arrowhead Pharmaceuticals' Depreciation And Amortization and Selling General Administrative is 0.86. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Arrowhead Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Arrowhead Pharmaceuticals' Depreciation And Amortization and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Arrowhead Pharmaceuticals Corp are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Depreciation And Amortization i.e., Arrowhead Pharmaceuticals' Depreciation And Amortization and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.86

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Selling General Administrative

Most indicators from Arrowhead Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.Selling General Administrative is likely to drop to about 79.1 M in 2024. Tax Provision is likely to drop to 1,710 in 2024

	2021	2022	2023	2024 (projected)
Gross Profit	232.8M	240.7M	276.8M	290.7M
Total Revenue	243.2M	240.7M	276.8M	290.7M

Gross Profit Total Revenue

Arrowhead Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Current Liabilities Total	Good Will	Short Term Investments
Total Assets		0.9	0.87	0.91	0.78	0.87	0.04	-0.92	0.79	0.66	0.99	0.25	0.99	0.4	0.87	-0.73	0.85	0.97	0.92	0.99	0.81	0.26	0.36	0.87	0.5	0.97
Short Long Term Debt Total	0.9		0.87	0.76	0.5	0.99	0.38	-0.88	0.9	0.38	0.91	0.23	0.87	0.1	0.72	-0.92	0.87	0.9	0.95	0.87	0.86	0.24	0.02	0.94	0.44	0.95
Other Current Liab	0.87	0.87		0.69	0.45	0.81	0.27	-0.87	0.61	0.39	0.89	0.64	0.85	0.18	0.74	-0.88	0.98	0.88	0.95	0.85	0.65	0.65	0.28	0.96	0.42	0.92
Total Current Liabilities	0.91	0.76	0.69		0.75	0.74	-0.16	-0.81	0.72	0.74	0.9	0.1	0.91	0.59	0.82	-0.55	0.69	0.86	0.82	0.91	0.85	0.11	0.56	0.72	0.44	0.81
Total Stockholder Equity	0.78	0.5	0.45	0.75		0.49	-0.4	-0.63	0.54	0.8	0.72	-0.15	0.81	0.47	0.78	-0.19	0.39	0.75	0.48	0.81	0.53	-0.14	0.39	0.38	0.45	0.66
Property Plant And Equipment Net	0.87	0.99	0.81	0.74	0.49		0.42	-0.86	0.94	0.33	0.89	0.12	0.83	0.08	0.7	-0.9	0.81	0.88	0.91	0.84	0.83	0.13	-0.07	0.9	0.45	0.93
Net Debt	0.04	0.38	0.27	-0.16	-0.4	0.42		-0.17	0.32	-0.71	0.14	0.14	-0.07	-0.29	-0.16	-0.55	0.26	0.08	0.29	-0.06	0.02	0.12	-0.62	0.39	-0.08	0.27
Retained Earnings	-0.92	-0.88	-0.87	-0.81	-0.63	-0.86	-0.17		-0.78	-0.51	-0.91	-0.28	-0.9	-0.26	-0.91	0.8	-0.86	-0.96	-0.9	-0.9	-0.75	-0.3	-0.23	-0.87	-0.58	-0.93
Accounts Payable	0.79	0.9	0.61	0.72	0.54	0.94	0.32	-0.78		0.36	0.79	-0.17	0.76	0.07	0.66	-0.74	0.63	0.8	0.76	0.77	0.81	-0.16	-0.17	0.73	0.46	0.83
Cash	0.66	0.38	0.39	0.74	0.8	0.33	-0.71	-0.51	0.36		0.56	0.05	0.73	0.39	0.71	-0.14	0.41	0.61	0.44	0.73	0.61	0.06	0.63	0.33	0.43	0.46
Non Current Assets Total	0.99	0.91	0.89	0.9	0.72	0.89	0.14	-0.91	0.79	0.56		0.27	0.96	0.43	0.83	-0.77	0.86	0.96	0.94	0.97	0.78	0.28	0.33	0.9	0.46	0.98
Non Currrent Assets Other	0.25	0.23	0.64	0.1	-0.15	0.12	0.14	-0.28	-0.17	0.05	0.27		0.25	0.0	0.2	-0.47	0.64	0.26	0.46	0.23	0.07	1.0	0.41	0.53	0.04	0.3
Cash And Short Term Investments	0.99	0.87	0.85	0.91	0.81	0.83	-0.07	-0.9	0.76	0.73	0.96	0.25		0.36	0.9	-0.7	0.83	0.97	0.89	1.0	0.82	0.26	0.38	0.84	0.52	0.94
Net Receivables	0.4	0.1	0.18	0.59	0.47	0.08	-0.29	-0.26	0.07	0.39	0.43	0.0	0.36		0.27	0.07	0.11	0.29	0.28	0.37	0.15	0.01	0.7	0.18	0.12	0.27
Common Stock Shares Outstanding	0.87	0.72	0.74	0.82	0.78	0.7	-0.16	-0.91	0.66	0.71	0.83	0.2	0.9	0.27		-0.55	0.73	0.94	0.75	0.89	0.71	0.21	0.38	0.68	0.64	0.82
Inventory	-0.73	-0.92	-0.88	-0.55	-0.19	-0.9	-0.55	0.8	-0.74	-0.14	-0.77	-0.47	-0.7	0.07	-0.55		-0.9	-0.75	-0.91	-0.69	-0.7	-0.48	0.07	-0.95	-0.31	-0.84
Other Current Assets	0.85	0.87	0.98	0.69	0.39	0.81	0.26	-0.86	0.63	0.41	0.86	0.64	0.83	0.11	0.73	-0.9		0.86	0.95	0.83	0.71	0.65	0.27	0.96	0.41	0.89
Other Stockholder Equity	0.97	0.9	0.88	0.86	0.75	0.88	0.08	-0.96	0.8	0.61	0.96	0.26	0.97	0.29	0.94	-0.75	0.86		0.91	0.97	0.78	0.27	0.28	0.87	0.59	0.97
Total Liab	0.92	0.95	0.95	0.82	0.48	0.91	0.29	-0.9	0.76	0.44	0.94	0.46	0.89	0.28	0.75	-0.91	0.95	0.91		0.89	0.8	0.46	0.27	0.99	0.42	0.95
Total Current Assets	0.99	0.87	0.85	0.91	0.81	0.84	-0.06	-0.9	0.77	0.73	0.97	0.23	1.0	0.37	0.89	-0.69	0.83	0.97	0.89		0.82	0.24	0.38	0.83	0.52	0.94
Short Term Debt	0.81	0.86	0.65	0.85	0.53	0.83	0.02	-0.75	0.81	0.61	0.78	0.07	0.82	0.15	0.71	-0.7	0.71	0.78	0.8	0.82		0.08	0.26	0.74	0.39	0.76
Common Stock	0.26	0.24	0.65	0.11	-0.14	0.13	0.12	-0.3	-0.16	0.06	0.28	1.0	0.26	0.01	0.21	-0.48	0.65	0.27	0.46	0.24	0.08		0.42	0.53	0.03	0.31
Current Deferred Revenue	0.36	0.02	0.28	0.56	0.39	-0.07	-0.62	-0.23	-0.17	0.63	0.33	0.41	0.38	0.7	0.38	0.07	0.27	0.28	0.27	0.38	0.26	0.42		0.18	0.06	0.18
Non Current Liabilities Total	0.87	0.94	0.96	0.72	0.38	0.9	0.39	-0.87	0.73	0.33	0.9	0.53	0.84	0.18	0.68	-0.95	0.96	0.87	0.99	0.83	0.74	0.53	0.18		0.39	0.93
Good Will	0.5	0.44	0.42	0.44	0.45	0.45	-0.08	-0.58	0.46	0.43	0.46	0.04	0.52	0.12	0.64	-0.31	0.41	0.59	0.42	0.52	0.39	0.03	0.06	0.39		0.47
Short Term Investments	0.97	0.95	0.92	0.81	0.66	0.93	0.27	-0.93	0.83	0.46	0.98	0.3	0.94	0.27	0.82	-0.84	0.89	0.97	0.95	0.94	0.76	0.31	0.18	0.93	0.47

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Other Current Liab	32.8M	33.3M	100.4M	58.2M	66.9M	70.2M
Total Current Liabilities	40.7M	146.5M	74.1M	105.5M	121.3M	127.3M
Total Stockholder Equity	461.8M	408.8M	106.0M	271.3M	312.0M	327.6M
Property Plant And Equipment Net	47.0M	66.0M	168.6M	335.6M	385.9M	405.2M
Net Debt	(122.4M)	(158.9M)	(26.4M)	4.3M	3.9M	4.0M
Retained Earnings	(503.8M)	(644.7M)	(820.8M)	(1.0B)	(923.4M)	(877.3M)
Accounts Payable	6.8M	9.5M	2.9M	35.9M	41.2M	43.3M
Cash	143.6M	184.4M	108.0M	110.9M	127.5M	133.9M
Non Current Assets Total	200.1M	325.6M	315.5M	346.0M	397.9M	417.8M
Non Currrent Assets Other	265.4K	272K	29.1M	210K	241.5K	229.4K
Cash And Short Term Investments	315.5M	367.8M	376.4M	403.6M	464.2M	487.4M
Net Receivables	661.4K	845.7K	10.3M	1.4M	1.6M	970.9K
Common Stock Shares Outstanding	100.7M	103.7M	105.4M	106.8M	122.8M	128.9M
Liabilities And Stockholders Equity	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Inventory	3.3M	4.3M	4.4M	(21.6M)	(19.5M)	(18.5M)
Other Current Assets	6.0M	6.6M	27.5M	15.9M	18.3M	19.2M
Other Stockholder Equity	965.4M	1.1B	1.2B	1.3B	1.5B	1.6B
Total Liab	60.7M	301.3M	586.0M	478.4M	550.1M	577.7M
Total Current Assets	322.4M	384.6M	376.4M	419.5M	482.4M	506.6M
Accumulated Other Comprehensive Income	18.4K	(69K)	(136K)	(3.2M)	(2.9M)	(2.8M)
Short Term Debt	1.1M	4.5M	5.6M	10.6M	12.1M	12.8M
Common Stock	194.7K	197K	106.0M	200K	230K	218.5K
Current Deferred Revenue	19.3M	111.1M	74.1M	866K	995.9K	946.1K
Non Current Liabilities Total	20.0M	154.8M	511.9M	372.9M	428.9M	450.3M
Short Term Investments	171.9M	183.4M	268.4M	292.7M	336.6M	353.5M
Intangible Assets	15.4M	13.7M	12.0M	10.3M	11.8M	10.2M
Other Liab	1.9M	8.7M	131.5M	56.0M	64.3M	44.0M
Net Tangible Assets	446.4M	395.2M	386.6M	261.1M	300.2M	291.5M
Capital Surpluse	582.9M	664.1M	965.4M	1.1B	1.2B	831.6M
Property Plant Equipment	47.0M	66.0M	168.6M	335.6M	385.9M	405.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arrowhead Depreciation And Amortization vs Selling General Administrative Analysis

Depreciation And Amortization vs Selling General Administrative

Depreciation And Amortization vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Depreciation And Amortization

Selling General Administrative

Arrowhead Pharmaceuticals fundamental ratios Correlations

Arrowhead Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arrowhead Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Arrowhead Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Non Currrent Assets Other
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Assets Total	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total

Other Stockholder Equity	- 0.96	Retained Earnings
Non Current Liabilities Total	- 0.95	Inventory
Short Term Investments	- 0.93	Retained Earnings
Inventory	- 0.92	Short Long Term Debt Total
Retained Earnings	- 0.92	Total Assets
Total Liab	- 0.91	Inventory